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Abstract 
We report on the development of photosensitizer-conjugated gold nanorods (MMP2P-GNR) 
in which photosensitizers were conjugated onto the surface of gold nanorods (GNR) via a 
protease-cleavable peptide linker. We hypothesized that fluorescence and phototoxicity of 
the conjugated photosensitizers would be suppressed in their native state, becoming activated 
only after cleavage by the target protease matrix metalloprotease-2 (MMP2). Quantitative 
analysis of the fluorescence and singlet oxygen generation (SOG) demonstrated that the 
MMP2P-GNR conjugate emitted fluorescence intensity corresponding to 0.4%  0.01% and an 
SOG efficiency of 0.89%  1.04% compared to free pyropheophorbide-a. From the in vitro cell 
studies using HT1080 cells that overexpress MMP2 and BT20 cells that lack MMP2, we ob-
served that fluorescence and SOG was mediated by the presence or absence of MMP2 in 
these cell lines. This novel activatable photosensitizing system may be useful for prote-
ase-mediated fluorescence imaging and subsequent photodynamic therapy for various can-
cers. 
Key words: Photodynamic therapy, Gold nanorod, Resonance energy transfer, Quenching, En-
zyme activatable 
Introduction 
Photodynamic therapy (PDT) describes the use 
of chemical photosensitizers combined with specific 
wavelengths of light. This form of therapy has been 
used  successfully  to  treat  cancers  and  is  capable  of 
overcoming side effects associated with conventional 
cancer treatments such as surgery, radiation therapy, 
and chemotherapy [1-2]. Photosensitizers accumulate 
in tumor tissues and are typically nontoxic to cells in 
the  absence  of  light.  When  photosensitizers  are  ex-
cited by light radiation of a specific wavelength, they 
react with the surrounding substrates or with molec-
ular oxygen to produce reactive oxygen species (ROS), 
which  selectively  damage  tumor  tissues  in  situ. 
However, current photosensitizers can also nonspe-
cifically accumulate in the skin or the eyes of patients. 
If, following PDT, these patients are exposed to light, 
such  as  sunlight  or  bright  indoor  light,  side  effects 
caused by damage to normal cells in these tissues can 
occur. Limited tumor selectivity and unfavorable bi-
odistribution  of  conventional  PDT  agents  have  re-
mained major obstacles to their clinical applications. 
“Activatable  PDT”  agents  have  recently  attracted  a 
great  deal  of  attention  as  a  strategy  to  overcome 
nonspecific  activation  of  phototoxicity.  In  an  ideal 
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PDT agent, generation of both fluorescence signal and 
cytotoxic singlet oxygen would be completely inhib-
ited in its native state, even upon light exposure. Their 
optical properties would  be selectively activated by 
stimuli such as enzymes [3-6] and pH [7-8]. Choi et al. 
reported  the  first  successful  in  vivo  results  demon-
strating the potential use of an activatable PDT agent 
in near-infrared fluorescence imaging and subsequent 
PDT of cancers. [3] Various mechanisms for control-
ling optical properties of photosensitizers have been 
tested,  including  self-quenching  between  the  same 
type of photosensitizers [3, 5-6, 9], quenching by or-
ganic  quenchers  [4,  10],  and  quenching  by  carbon 
nanotubes [11] and gold nanorods [12].  
Herein, we report on photosensitizer-conjugated 
gold nanorods (Figure 1), in which photosensitizers 
were  conjugated  onto  the  surface  of  gold  nanorods 
(GNRs) via a protease-cleavable peptide linker. GNRs 
have immense absorption coefficients, 104- to 106-fold 
higher than those of conventional organic dyes, and 
therefore, may serve as ultraefficient energy quench-
ers  of  excited  photosensitizers  through  their  sur-
face-energy-transfer  properties  [13-14].  In  addition, 
gold nanoparticles, including GNRs, can quench the 
excited energy of fluorochromes even at a distance of 
~40 nm [15]. Therefore, we expected the fluorescence 
and phototoxicity of the photosensitizers conjugated 
on the surface of GNRs to be suppressed in their na-
tive  state,  and  activated  following  release  from  the 
GNR surface by the action of a target protease. This 
strategy may allow a photodynamic reaction to take 
place in a target area with greater selectivity and effi-
ciency. 
 
 
Figure 1. A concept of enzyme activatable fluorescence imaging and photodynamic therapy using a photosensitizer-conjugated gold 
nanorod (MMP2P-GNR). Box: Structure of the MMP2P containing MMP2-cleavable peptide sequence and photosensitizer. Arrow indicates 
cleavable site by MMP2 activity. 
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In  this  study,  the  sequence  GPLGVRG 
(-Gly-Pro-Leu-Gly-Val-Arg-Gly-), which is specific to 
the  matrix  metalloproteinase-2  (MMP2)  substrate 
(Figure 1), was introduced as the target for enzymatic 
hydrolysis by MMP2 [16]. Matrix metalloproteinases 
(MMPs) are zinc-dependent endopeptidases and are 
known to play key roles in tumor growth, progres-
sion, and metastasis as well as in dysregulated angi-
ogenesis [17-20]. Therefore, MMPs, including MMP2, 
are considered important therapeutic and diagnostic 
targets  for  the  treatment  and  detection  of  human 
cancers. Cysteine was added to the peptide sequence 
in order to conjugate MMP2P on the surface of the 
GNRs via thiol chemistry. 
Materials and methods  
Materials 
Gold  (Ⅲ)  chloride  trihydrate  (HAuCl43H2O, 
99.9%),  sodium  borohydride  (NaBH4,  99%),  silver 
nitrate (AgNO3, 99%) and L-ascorbic acid (AA, 99%), 
and  hexadecyltrimethylammonium  bromide  (CTAB, 
99%) were purchased from Sigma-Aldrich (St. Louis, 
MO). Pyropheophorbide-a (PPa) was purchased from 
Frontier Scientific, Inc. (Logan, Utah). Singlet oxygen 
sensor green was purchased from Molecular Probes. 
Ultrapure  deionized  water  was  used  in  all  experi-
ments.  HT1080  cells  (human  fibrosarcoma  cell  line) 
overexpressing MMP2 and BT20 cells (human mam-
mary adenocarcinoma cell line), which lack detectable 
MMP2 expression [16], were obtained from American 
Type Culture Collection (ATCC, Rockville, MD). Cell 
lines were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS), (GIBCO, Invitrogen) in a humidi-
fied 5% CO2 incubator at 37°C.  
Preparation of gold nanorod solution 
Gold  nanorods  were  prepared  using  a 
seed-mediated  method  as  described  previously [12, 
21]. In brief, CTAB was dissolved in deionized water 
(DW) to a molarity of 100 mM; 7.5 ml of this CTAB 
aqueous  solution  was  mixed  with  250  L  of  10mM 
HAuCl4 aqueous solution, followed by the addition of 
600 L of 10mM NaBH4 aqueous solution. The mix-
ture was stirred for 2 min, and maintained at 25 °C for 
2 h to prepare a seed solution. 
Meanwhile, 1.7 mL  of 10mM HAuCl4 aqueous 
solution was added to 40 mL of 100mM CTAB aque-
ous solution, followed by the sequential addition of 
250 L of 10 mM AgNO3 aqueous solution and 270 L 
of 100 mM ascorbic acid. At this point, 420 L of the 
seed solution was added, and then maintained to re-
act for 12 h. Thereafter, the reaction mixture was cen-
trifuged at 15000 × g at 25 °C for 15 min, thereby ob-
taining a CTAB-coated gold nanorod. 
Preparation of photosensitizer-peptide conju-
gate (MMP2P) 
MMP2-cleavable peptide substrate coupled with 
PPa  (MMP2P)  was  purchased  from  Peptron  Inc. 
(Daejeon, Republic of Korea). Supplementary Materi-
al:  Figure  S1  briefly  summarizes  the  procedure  of 
MMP2P  synthesis.  An  HPLC  and  mass  analyses  of 
MMP2P shows a purity of about 98%, and a molecular 
weight of 2039 g/mol (Supplementary Material: Fig-
ure S2 and S3). 
Preparation of MMP2P-gold nanorod 
(MMP2P-GNR) conjugate  
The  centrifuged  CTAB-coated  GNRs  were  re-
suspended in 1 mL of DW to remove excess CTAB. 
The concentration of the GNR solution was 100 nM 
after  resuspension.  An  aqueous  solution  was  pre-
pared by dissolving the MMP2P to a concentration of 
1 mM, of which 200 µL was added to the dispersion in 
addition to 100 L of 2 mM K2CO3 aqueous solution 
and allowed to react at room temperature for 5 days. 
The resulting solution was dialyzed in DW using an 
ultrafiltration  membrane  with  a  molecular  weight 
cut-off (MWCO) of 50,000 Da to remove MMP2P that 
did not participate in the reaction with the GNRs. The 
remaining solution represented MMP2P-GNR conju-
gates in which the photosensitizer-oligopeptide com-
bination was linked with the GNRs. 
To calculate the number of conjugated MMP2P 
per  GNR,  the  absorption  spectrum  of  the  purified 
MMP2P-GNR was measured in both DW (Figure 2B) 
and  dimethylformamide  (DMF)  using  a  UV/Vis 
scanning spectrophotometer (DU730, Beckman). The 
CTAB-coated GNR has a molar absorption coefficient 
of  4.6  ×  109  M-1cm-1  at  785  nm  in  DW  [22].  PPa  is 
known to have a molar absorption coefficient of 9.98 × 
104 M-1cm-1 at 413 nm in DMF [23]. These values were 
used  to  calculate  the  average  number  of  MMP2P 
conjugated per GNR in the MMP2P-GNR conjugates. 
Analysis of fluorescence and singlet oxygen gen-
eration (SOG) from the MMP2P-GNR conjugate 
To observe fluorescence quenching characteris-
tics, the MMP2P-GNR conjugates were dissolved in 
phosphate-buffered  saline  ([PBS],  6.7  mM;  pH  7.4; 
NaCl, 154 mM), and their fluorescence spectra were 
measured (Ex. 410 nm). In this study, a concentration 
equivalent to 1 μM PPa was used for each solution. 
For comparison, free PPa was dissolved in PBS con-
taining  1%  (v/v)  Tween  20  to  prevent  fluorescence 
quenching due to aggregation (Supplementary Mate-
rial: Figure S4A). Theranostics 2012, 2(2) 
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To observe an inhibitory characteristic with re-
spect to SOG, both singlet oxygen sensor green and 
the  MMP2P-GNR  conjugate  were  dissolved  in  PBS 
solution  saturated  with  oxygen  gas.  For  the  meas-
urement of SOG from free PPa, both singlet oxygen 
sensor green and PPa were dissolved in PBS contain-
ing 1% (v/v) Tween 20. The final concentration of free 
PPa and MMP2P-GNR in the aqueous solutions was 
equivalent to 1 μM PPa. SOG from the MMP2P-GNR 
conjugate was quantified by comparing to that from 
free PPa. Each solution was irradiated with a CW laser 
beam at 670 nm (irradiation dose rate, 68 mW cm-2 
and irradiation dose, 2 J cm-2). All experiments were 
performed in triplicate. 
Dispersion stability of MMP2P-GNR 
To  check  the  dispersion  stability  of 
MMP2P-GNR  in  the  various  aqueous  solutions, 
MMP2P-GNRs were dispersed in each of PBS and a 
cell  culture  medium  (Dulbecco’s  modified  Eagle’s 
medium  without  phenol  red)  containing  10%  fetal 
bovine serum (FBS). The final concentration of GNRs 
in the solutions was adjusted to 0.5 nM. The solutions 
were maintained at 25 °C for 24 h. UV/Vis spectra of 
the sample solutions were taken after 10 min and 24 h 
of incubation at 25 °C 
In vitro cell study for fluorescence activation of 
MMP2P-GNR 
MMP2-positive  HT1080  cells  and 
MMP2-negative  BT20  cells  in  culture  media  were 
plated  onto  a  LabTek  II  Chambered  Coverglass 
(Nalge  Nunc  International  Corp.)  at  a  density  of 
90,000 cells/well, and incubated for 24 h to allow for 
cell  attachment.  Thereafter,  MMP2P-GNR  solution 
was diluted with culture medium to achieve a con-
centration equivalent to 5 M PPa, and added at 600 
L per well. The cells were incubated at 37 °C for 15 h 
after which the culture medium was removed, and the 
cells were washed 3 times with fresh culture medium. 
Fluorescence  images  (Ex.  405  nm  and  Em.  646–753 
nm)  were  acquired  using  a  confocal  laser  scanning 
microscope (ZEISS LSM 510 META).  
In vitro phototoxicity test  
For in vitro phototoxicity tests, HT1080 and BT20 
cells were seeded in 96-well plates at a density of 9,000 
cells/well.  The  next  day,  the  photosensitiz-
er-oligopeptide  conjugate  (MMP2P)  and  the  photo-
sensitizer-  gold  nanorod  conjugate  (MMP2P-GNR) 
were diluted in cell culture medium to obtain a con-
centration equivalent to 5 M PPa. The existing cul-
ture medium was replaced with 200 L of fresh me-
dium  containing  MMP2P  or  the  MMP2P-GNR  con-
jugate, and the cells were incubated for 15 h. Mean-
while,  for  the  untreated  control  group,  the  same 
volume of a fresh culture medium with no photosen-
sitizer included was added to a plate and incubated 
for 15 h. Thereafter, the cells were washed twice with 
cell  culture  medium,  and  for  the  PDT  group,  light 
irradiation was carried out with a 670-nm CW laser 
beam at a dose of 10 J/cm2 and at a dose rate of 40 
mW/cm2. After 24 h, cell viability was measured by 
MTT analysis. Cell viability was calculated as a per-
centage  compared  to  untreated  control  cells.  Dark 
toxicity of the MMP2P and the MMP2P-GNR conju-
gate  was  also  evaluated  by  incubating  these  com-
pounds  for  15  h  at  the  same  concentration  without 
light treatment.  
For  the  morphological  analysis  following  light 
illumination, HT1080 and BT20 cells in culture media 
were plated onto a LabTek II Chambered Coverglass 
(Nalge  Nunc  International  Corp.)  at  a  density  of 
90,000 cells/well, and incubated for 24 h to allow for 
cell  attachment.  Thereafter,  MMP2P-GNR  solution 
was  diluted  in  culture  medium  to  a  concentration 
equivalent to 5 M PPa, and added at 600 L per well. 
The cells were incubated at 37  °C for 15 h. Culture 
medium was then removed and the cells were washed 
3 times with a fresh culture medium before receiving 
light  treatment  with  a  670-nm  CW  laser  beam  at  a 
dose of 10 J/cm2 and at a dose rate of 40 mW/cm2. 
Fluorescence and transmittance images were obtained 
using a confocal laser scanning microscope (Ex. 405 
nm and Em. 646–753 nm) immediately following PDT. 
Results & Discussion 
A transmission electron microscopy (TEM) im-
age of the CTAB-coated GNR showed that the average 
length and width was 33.6  3.7 and 8.7  0.9 nm, re-
spectively (aspect ratio, ~3.9:1) (Figure 2A). From the 
analysis  of  the  UV/Vis  absorption  spectrum,  the 
maximum absorption wavelength of the CTAB-coated 
GNR  is  about  766  nm,  and  a  strong  plasmon  reso-
nance  spectrum  was  observed  in  the  fluorescence 
wavelength of PPa, i.e., 650 to 780 nm (Figure 2B). The 
UV/Vis absorption spectrum of the MMP2P-GNR in 
PBS  solution  shows  additional  absorption  peaks  at 
387 nm (Soret band) and ~ 670 nm (Q band), which 
represent  absorption  peaks  by  the  photosensitizer 
PPa. Blue shift and broadening of the Soret band of 
PPa indicates that there was an aggregation between 
the  conjugated  photosensitizers.  When  the 
MMP2P-GNR was dissolved in DMF (Supplementary 
Material:  Figure  S5),  narrow  and  clear  peaks  were 
shown at 413 and 670 nm, and this is a typical feature 
of  monomeric  PPa.  The  molar  ratio  of  conjugated 
MMP2P per GNR was calculated to be 4,960:1 from 
the UV/Vis spectrums of MMP2P-GNR in PBS and Theranostics 2012, 2(2) 
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DMF solutions. 
As mentioned above, the main plasmonic reso-
nance band of the GNRs in the near-infrared region 
significantly  overlapped  with  the  emission  band  of 
PPa (Figure 2B). Therefore, we assumed that fluores-
cence and SOG of PPa may be inhibited due to energy 
transfer from the excited PPa to the GNRs and also 
partly  due  to  self-quenching  between  the  bound 
photosensitizers. Fluorescence spectra of the free PPa 
and  MMP2P-GNR  confirms  the  ultra-efficient 
quenching of the fluorescence in MMP2P-GNR com-
pared with free PPa (Figure 2C). From the quantita-
tive  analysis  of  the  fluorescence  and  SOG,  the 
MMP2P-GNR conjugate emitted a fluorescence inten-
sity corresponding to 0.4%  0.01% and an SOG effi-
ciency of 0.89%  1.04% compared to free PPa (Figure 
2D). This confirms that, when PPa is adjacent to the 
GNR surface, the fluorescent signal and SOG are ef-
fectively inhibited. In  other words, the fluorescence 
and SOG of PPa recover when the compound is re-
leased from the GNR surface. 
To check the dispersion stability, MMP2P-GNR 
was dispersed in each of PBS solution and cell culture 
medium containing 10% fetal bovine serum (FBS). The 
UV/Vis  spectra  of  all  the  test  solutions  were  taken 
after 10 min and 24 h of incubation at 25 °C (Supple-
mentary Material: Figure S6). The UV/Vis spectra of 
all the test solutions did not change for 24 h, indicat-
ing that there was no aggregation or precipitation of 
GNRs. 
We then evaluated protease-mediated activation 
of fluorescence and SOG in vitro using HT1080 cells 
(human  fibrosarcoma  cell  line),  which  overexpress 
MMP2, and BT20 cells (human mammary adenocar-
cinoma cell line), which lack detectable expression of 
MMP2. Figure 3 shows fluorescence in both cell lines 
treated  with  MMP2P-GNR.  The  cancer  cell  line 
HT1080 emitted a much stronger fluorescence com-
pared to BT20 cells. This result suggests that in the 
HT1080  cells,  the  peptide  substrate  of  the 
MMP2P-GNR conjugate was cleaved by the MMP2, 
separating  the  photosensitizer  from  the  GNR,  and 
thereby facilitating the emission of fluorescent signal. 
We  can  speculate  that  if  the  photosensitizer-GNR 
conjugate were to be administered to a patient, detec-
tion of fluorescence following light radiation would 
accurately identify tissues in which MMP2 was over-
expressed.  
 
Figure 2. Development and characterization of MMP2P-GNR. (A) Transmission electron microscopy (TEM) image of CTAB-coated 
GNRs.  (B) UV/Vis  absorption  spectrum  of  the  CTAB-coated GNR  and MMP2P-GNR.  (C) Fluorescence  spectra  of free  PPa  and 
MMP2P-GNR (Ex. 410 nm and Em. 600–800 nm). Box: fluorescence spectrum of MMP2P-GNR conjugate. (D) Relevant fluorescence 
intensity (left: Ex. 410 nm and Em. 677 nm) and SOG (right) of 1 M of the MMP2P-GNR conjugate. (The measured fluorescence and SOG 
of 1 M PPa was converted to 100%).  Theranostics 2012, 2(2) 
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When the cell lines  were treated with  MMP2P 
and  when  PDT  was  performed,  both  HT1080  and 
BT20 exhibited low cell viabilities representing high 
phototoxicity  (Figure  4).  However,  when  the  cells 
were  treated  with  MMP2P-GNR  followed  by  PDT, 
HT1080 exhibited a cell viability of 16%, whereas the 
cell line BT20 exhibited a cell viability of 63%. This 
supports the theory that the phototoxicity induced by 
the MMP2P-GNRs was the result of selective activa-
tion  by  the  MMP2  present  in  the  HT1080  cell  line. 
Since  it  is  generally  believed  that  nano-sized  drug 
carriers  accumulate  at  tumor  sites  by  the 
so-called  enhanced  permeation  and  retention 
effect  [24], an improved outcome of selective 
PDT in vivo is expected. No dark toxicities were 
observed in both cell lines when treated with 
either MMP2P or MMP2P-GNR.  
Blebbing of the cell membrane of HT1080 
cells  was  observed  upon  light  illumination 
whereas no apparent change in the cell mor-
phologies was shown in the BT20 cells (Figure 
5). This is likely a result of the ROS generated 
from photosensitizers that have been activated 
by the MMP2 present in the HT1080 cell line, 
and  this  subsequently  leads  to  the  observed 
disruption of the cell membrane.  
Fluorescence and SOG were efficiently inhibited 
by conjugating photosensitizers onto gold nanorods 
via  a  protease-cleavable  peptide  linker. 
MMP2P-GNRs  demonstrated  selective  activation  in 
near-infrared fluorescence and phototoxicity in cells 
in which MMP2 is overexpressed. This novel design 
of an enzyme-activatable PDT agent may be useful in 
near-infrared fluorescence imaging and in subsequent 
PDT of various disease sites in which a specific pro-
tease is overexpressed. 
 
Figure  3.  Confocal  microscopy  images  of  unfixed 
HT1080 and BT20 cells treated with MMP2P-GNR (5 M 
PPa eq.). Top row: fluorescence images of the cells (Ex. 
405 nm and Em. 646–753 nm). The fluorescence signals 
are  from  PPa.  Bottom  row:  transmitted  light  images 
merged with the fluorescence image above (Magnification: 
80).  
 
 
 
 
 
Figure 4. In vitro photodynamic efficacy of MMP2P and MMP2P-GNR. (a) HT1080 (MMP2-positive) and (b) BT20 (MMP2-negative) cells 
were treated with either 5 M PPa equivalent MMP2P or MMP2P-GNR for 15 h in the dark prior to light illumination with 670-nm diode 
laser. Cell viability was determined by MTT assay. Data represent mean ± S.D. (n = 4). Theranostics 2012, 2(2) 
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Figure 5. Confocal microscopy images of unfixed HT1080 and BT20 cells treated with MMP2P-GNR (5 M PPa eq.) followed by light 
illumination (light dose, 10 J/cm2 and light dose rate, 40 mW/cm2). Top row: fluorescence images of the cells (Ex. 405 nm and Em. 646–753 
nm). The fluorescence signals are from PPa. Bottom row: transmitted light images merged with the fluorescence image above (Magnifi-
cation, 80). 
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Fig.S1-S6. http://www.thno.org/v02p0190s1.pdf 
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